Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.34 |
| ▸ | HRH1 | P35367 | 4/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7950524 | 0.81 | MTNR1A (0.33) | HTR2APTGDR2HRH1HTR2C | |
| Hydrochloric Acid SCHEMBL29960643 | 0.80 | HTR2A (0.46) | HTR2AHRH1SLC6A2SLC6A4HTR2C | |
| Hydrochloric Acid SCHEMBL29960736 | 0.80 | HTR2A (0.47) | HTR2AHRH1SLC6A2SLC6A4HTR2C | |
| SCHEMBL19828084 | 0.79 | POLB (0.43) | HTR2AHRH1SLC6A2SLC6A4CYP2D6 | |
| SCHEMBL29960263 | 0.79 | HTR2A (0.47) | HTR2AHRH1SLC6A2SLC6A4HTR2C | |
| SCHEMBL29960735 | 0.77 | MEN1 (0.31) | HTR2AHRH1HTR2C | |
| SCHEMBL19852205 | 0.77 | NOTUM (0.33) | HTR2APTGDR2HRH1HTR2C | |
| SCHEMBL17061157 | 0.77 | NOTUM (0.33) | HTR2APTGDR2HRH1HTR2C | |
| SCHEMBL23843790 | 0.77 | HTR2A (0.44) | HTR2AHRH1HTR2C | |
| SCHEMBL8402502 | 0.76 | ADRA2A (0.40) | HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295181-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | Sanford Burnham Prebys Medical Discovery Institute | 2023-09-21 | — | — | US | disclosed |
| US-20230024302-A1 | 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS | ARCUS BIOSCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20230009608-A1 | GRK2 INHIBITORS AND USES THEREOF | SONATA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| CN-115521325-A | Boronic acid derivatives | 首药控股(北京)股份有限公司 | 2022-12-27 | — | — | CN | disclosed |
| US-8283357-B2 | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-20100311794-A1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20080306136-A1 | Substituted Ureas and Carbamates | ELAN PHARMACEUTICALS, INC. | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230009608-A1 | GRK2 INHIBITORS AND USES THEREOF | GRK2, GRK3, GRK1 | HTR2A 908/4885PTGDR2 476/4885HRH1 2815/4885 |
| US-20230024302-A1 | 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS | PIK3CA, PIK3CG, PIK3CD | HTR2A 3224/4885PTGDR2 1159/4885HRH1 2286/4885 |
| US-20100311794-A1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC3 | HTR2A 2778/4885PTGDR2 4567/4885HRH1 552/4885 |
| US-20080306136-A1 | Substituted Ureas and Carbamates | BACE1, BACE2, APP | HTR2A 4634/4885PTGDR2 4303/4885HRH1 958/4885 |
| US-20230295181-A1 | INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS | API5, XIAP, BIRC5 | HTR2A 4276/4885PTGDR2 4515/4885HRH1 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.